[
    [
        {
            "time": "",
            "original_text": "欧普康视(300595.SZ)一季度净利润升263.7%至1.38亿元",
            "features": {
                "keywords": [
                    "欧普康视",
                    "净利润",
                    "一季度",
                    "增长",
                    "263.7%",
                    "1.38亿元"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "欧普康视(300595.SZ)一季度净利润升263.7%至1.38亿元",
                "Correlation": 10,
                "Sentiment": 10,
                "Importance": 9,
                "Impact": 9,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "欧普康视(300595.SZ)第一季度归母净利润同比增263.7%至1.38亿元",
            "features": {
                "keywords": [
                    "欧普康视",
                    "归母净利润",
                    "第一季度",
                    "同比增长",
                    "263.7%",
                    "1.38亿元"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "欧普康视(300595.SZ)第一季度归母净利润同比增263.7%至1.38亿元",
                "Correlation": 10,
                "Sentiment": 10,
                "Importance": 9,
                "Impact": 9,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "欧普康视：一季度净利润同比增长263.7%",
            "features": {
                "keywords": [
                    "欧普康视",
                    "净利润",
                    "一季度",
                    "同比增长",
                    "263.7%"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "欧普康视：一季度净利润同比增长263.7%",
                "Correlation": 10,
                "Sentiment": 10,
                "Importance": 9,
                "Impact": 9,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "医药生物行业跨市场周报：小阳春行情渐入佳境 核心资产与二三线齐发力",
            "features": {
                "keywords": [
                    "医药生物",
                    "小阳春行情",
                    "核心资产",
                    "二三线",
                    "齐发力"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药生物行业跨市场周报：小阳春行情渐入佳境 核心资产与二三线齐发力",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 2,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "八大券商主题策略：深度挖掘疫苗产业链机会 核心资产标的名单曝光",
            "features": {
                "keywords": [
                    "券商",
                    "主题策略",
                    "疫苗产业链",
                    "核心资产",
                    "标的名单"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药生物",
                    "疫苗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "八大券商主题策略：深度挖掘疫苗产业链机会 核心资产标的名单曝光",
                "Correlation": 5,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 2,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        }
    ]
]